SummaryTo be eligible for this trial, patients must have metastatic castration resistant prostate cancer (mCRPC) that has progressed with a novel AR targeted agent (abiraterone and/or enzalutamide and/or apalutamide) and has not previously been exposed to platinums, PARP inhibitors or 177Lu-PSMA. Patients can have had prior exposure to docetaxel in the chemotherapy naÃ¯ve setting or castrate setting. Eligible patients will be enrolled in the trial in two stages: a dose escalation and expansion stage. Depending on the stage of enrolment, patients will receive either escalating or fixed 7.4 GBq of 177Lu-PSMA every 6 weeks together with olaparib on days 2-15 of each cycle. A cycle is 42 days long. Patients will receive up to 4 cycles of treatment.
This trial is treating patients with castration resistant prostate cancer.
Use the hyperlinks, where available to access additional clinical trial information.
Peter MacCallum Cancer Centre
177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer